

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

PROFIT WARNING OF THE RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2019

This announcement is made by Common Splendor International Health Industry Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, subject to the finalisation of its unaudited condensed consolidated financial results for the six months ended 30 June 2019 (the “**Current Period**”), the Group is expected to record a profit before tax of around HK\$6.9 million for the Current Period, representing a decrease of approximately 60% in the Group’s profit before tax as compared to the profit before tax of approximately HK\$17.6 million for the six months ended 30 June 2018 (the “**Corresponding Period**”). The major factors attributable to the reduction in the Group’s profit before tax for the Current Period include, inter alia, (i) the decrease in gross profit and the lower gross profit margin of the Group’s products as compared to the Corresponding Period, which was mainly caused by an increase in costs of raw materials for the production; and (ii) the absence of a gain on fair value change on derivative financial liabilities as compared to the Corresponding Period, where the Group recorded a fair value gain of HK\$7.3 million.

The information contained in this announcement is only based on the preliminary assessment by the Board based on the information currently available to the Company, including the management accounts of the Group, which has neither been reviewed by the audit committee of the Board nor reviewed or audited by the external auditors of the Company. Further details of the Group's financial performance will be disclosed when the Company finalises and announces its financial results for the Current Period, which is currently expected to be published on 28 August 2019.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 21 August 2019

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang, Mr. Hou Kaiwen and Mr. Wong Kin Man as non-executive Directors; and Mr. Mai Yang Guang, Mr. Lam Chi Wing and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.